Inozyme Pharma (NASDAQ:INZY) Stock, Quote.Headers.trade-ideas

Inozyme Pharma

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

Pharmaceutics,Laboratory:,Pipette,Dropping,Yellow,Liquid,Into,Test,Tubes,,Medical

Biotech

News

Health Care

Movers

Trading Ideas

General

INZY

Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701&#39;s potential to treat rare diseases like ENPP1 and ABCC6 deficiencies.

Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock &#39;Could Be Worth A Look&#39;

xr:d:DAFpQHWcfko:2,j:5894483215029085173,t:23072108

Initiation

Markets

Analyst Ratings

RKLB

This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Nikola Motor

Intraday Update

ALTS

ALZN

APDN

APPS

CING

CLOV

FFIE

FHTX

FUBO

GNLN

GOVX

IBRX

LLAP

LQDA

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NKLA

SEEL

SIDU

SOND

TELO

TGTX

TNXP

TOVX

VALN

VRAX

XPER

ZVRA

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Inozyme Pharma Inc

Redburn Atlantic analyst Peter Low downgrades BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) from Buy to Neutral.

Downgrades

Redburn Atlantic Downgrades BP to Neutral

RBC Capital analyst Nik Modi downgrades Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) from Outperform to Sector Perform and announces $24 price target.

Price Target

KVUE

RBC Capital Downgrades Kenvue to Sector Perform, Announces $24 Price Target

Zuora customers can instantly activate its&nbsp;AI paywall&nbsp;in minutes for a deeper understanding of subscriber behavior to drive conversion and revenue growth.

Zuora Reveals New AI Enhancements At Subscribed Live London

Under the terms of the collaboration agreement, Generate will receive a total upfront payment of&nbsp;$65 million&nbsp;in cash from Novartis, which includes&nbsp;$15 million&nbsp;for the purchase of equity in Generate. Generate is also eligible to receive more than&nbsp;$1 billion&nbsp;in performance-based milestone payments, in addition to tiered royalties up to low double-digits. The number of targets and therapeutic areas are not being disclosed.

Contracts

Generate:Biomedicines Enters Multi-target Collaboration With Novartis To Discover, Develop Protein Therapeutics Across Multiple Disease Areas; Potential Total Transaction Valued At More Than $1B

IMMP

Immutep Received €2.19M R&D Tax Incentive Payment From French Government Under CIR Scheme

Macquarie analyst Ellie Jiang initiates coverage on DiDi Global (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DIDIY#OTC">DIDIY</a>) with a Outperform rating and announces Price Target of $5.5.

DIDI GLOBAL INC S/ADR by DiDi Global Inc.

DIDIY

Macquarie Initiates Coverage On DiDi Global with Outperform Rating, Announces Price Target of $5.5

BCLI

BrainStorm Cell Therapeutics Plans To Share Latest Update On NurOwn At This Year's NEALS Meeting

Catalyst Pharmaceuticals, Inc.&nbsp;("Catalyst" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") to commercialize FIRDAPSE&#xAE; (amifampridine) Tablets 10 mg for treatment of patients with Lambert-Eaton Myasthenic Syndrome ("LEMS") in Japan. This approval marks a pivotal advancement in the treatment of LEMS, a rare autoimmune disorder that can severely impact quality of life and represents a significant step forward in addressing the unmet needs of patients affected by LEMS in Japan.
"We are pleased that our partner, DyDo, has secured regulatory approval for FIRDAPSE in Japan. This represents a meaningful milestone, bringing renewed hope to patients and further affirming FIRDAPSE's proven effectiveness in the treatment of LEMS," said Richard J. Daly, Catalyst's President and Chief Executive Officer. "This achievement underscores our unwavering commitment to advancing patient care. We appreciate the collaborative efforts of our partner in securing this approval, and we remain focused on expanding our innovative rare disease product portfolio beyond the U.S. to make a meaningful impact on patients' lives worldwide."
FIRDAPSE (amifampridine) is a leading therapy indicated in the United States for the treatment of LEMS in adults and pediatric patients six years of age and older. LEMS is a rare autoimmune disorder characterized by muscle weakness and fatigue. About 50% of people with LEMS have underlying cancer, as LEMS is observed in approximately 3% of small-cell lung cancer patients. FIRDAPSE is the only U.S. FDA-approved, evidence-based treatment for LEMS. As a cornerstone of Catalyst's commitment to serving those with rare diseases, FIRDAPSE is supported in the U.S. by a comprehensive patient support program to help ensure accessibility and assistance for eligible U.S. patients.

Government

Regulations

CPRX

Catalyst Pharma's FIRDAPSE Approved in Japan for Rare Autoimmune Disorder Lambert-Eaton Myasthenic Syndrome ("LEMS")

Buybacks

ARLO

Arlo Technologies Plans Repurchase Of Up To An Aggregate Of $50M Of Shares Of Its Common Stock

The application to the PMDA was based on the efficacy and safety data from TRAILBLAZER-ALZ 2 Phase 3 clinical study.

Eli Lilly Says Japan Has Approved Kisunla (Donanemab-azbt, 350 Mg/20 mL Every Four Weeks Injection For IV Infusion) For Early Symptomatic Alzheimer's Disease

Revelation Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revbiosciences.com%2Fnews73&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=topline+data+from+the+Phase+1+clinical+study+of+Gemini&amp;index=1&amp;md5=251ba51b272b745c89d17af8755c3483">topline data from the Phase 1 clinical study of Gemini</a> released on June 24, 2024.
Using high sensitivity serum IL-10 biomarker analysis to gain further insight into Gemini's capability for resolution of inflammation, Revelation tested samples from the Phase 1 clinical study. It was found that Gemini induced statistically significant, dose dependent changes in circulatory IL-10 at 2 hours post-dose, with a p-value of &lt; 0.05 or greater, at each of the low, mid, and high dose levels, as shown in Figure 1. The change in IL-10 observed for treatment groups relative to placebo, were a 27-fold increase, 162-fold increase, and 309-fold increase for the low, mid, and high dose groups, respectively.
IL-10 is a potent anti-inflammatory protein that downregulates pro-inflammatory cytokines and is an active contributor to initiating reduction of inflammation. The significant increase of anti-inflammatory IL-10 with no significant increase in pro-inflammatory IL-1β and TNF-α confirms TLR4 binding unique to Gemini, and is further evidence of the reprogramming of the innate immune response, enabling Gemini to initiate resolution of inflammation and promote the healing process.
The observed increase of IL-10 in humans is consistent with prior preclinical studies performed by Revelation where an increase in IL-10 was observed in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revbiosciences.com%2Fnews60&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=healthy+animals&amp;index=2&amp;md5=dba735604f9f7922b050fc373a1fd8dd">healthy animals</a> as well as efficacy models, including the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fstatic1.squarespace.com%2Fstatic%2F5f536d50b94bfb444769fc95%2Ft%2F65f114641526fa578482eaac%2F1710298213540%2FPrevention%2Bof%2BAKI%2Bw%2BGemini%2BCRRT%2BPresentation%2Band%2BPoster%2B2024.pdf&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=ischemia%2Freperfusion+model+of+acute+kidney+injury&amp;index=3&amp;md5=9a89ab3850d72e11e309d58197a508fc">ischemia/reperfusion model of acute kidney injury</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revbiosciences.com%2Fnews48&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=unilateral+ureteral+obstruction+model+of+kidney+injury&amp;index=4&amp;md5=c3be07701ccf2cae5a96619526bd4589">unilateral ureteral obstruction model of kidney injury</a>. This demonstrates the potential for Gemini in our target indications, including prevention of AKI following cardiac surgery.

REVB

Revelation Biosciences Observes IL-10 Increase in Phase 1 Gemini Trial

Keybanc analyst Jason Celino initiates coverage on Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) with a Overweight rating and announces Price Target of $70.

Keybanc Initiates Coverage On Dayforce with Overweight Rating, Announces Price Target of $70

KBR was awarded this contract under the Department of Defense Information Analysis Center&#39;s (DoDIAC) multiple-award contract (MAC) vehicle. These IAC MAC task orders (TOs) are awarded by the U.S. Air Force&#39;s 774th Enterprise Sourcing Squadron to develop and create new knowledge for the enhancement of the DTIC repository and the R&amp;D and S&amp;T community.

KBR Bags Estimated $113M Task Order To Perform Aeronautical Systems Research, Development, Test And Evaluation For AFLCMC/WL At Wright-Patterson Air Force Base, Ohio Over 5 Years

Nuvve Holding Corp. ("Nuvve") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>), a global technology leader accelerating the electrification of transportation through its proprietary energy management and aggregation platform, is proud to announce the commissioning of its first deployment in New Mexico in collaboration with Las Cruces Public Schools. This project marks a significant milestone in expanding electric vehicle infrastructure within the educational sector.
&nbsp;
Las Cruces Public Schools, the second largest school district in New Mexico, engaged Nuvve to deploy 5 Vehicle-to-Grid (V2G)-capable DC Fast Chargers and 7 Nuvve Level II PowerPorts, aimed at supporting the school district's transition to electric school buses and other electric vehicles. Gregory Poilasne, CEO of Nuvve, states, "We're thrilled to partner with Las Cruces Public Schools, a trailblazer amongst New Mexico's school districts, on this groundbreaking project in New Mexico. This collaboration exemplifies our mission to support the electrification of transportation within educational institutions, fostering a greener future for our children. By integrating our advanced charging solutions, we're not only reducing emissions but also creating significant energy savings for the district with future V2G revenues."
Daoud Chaaya, Thomas Built Buses VP-Sales, Aftermarket and Marketing, shares, "This project represents the first commissioned Nuvve chargers with Thomas buses in the state of New Mexico. The success of this deployment will pave the way for broader adoption of electric school buses across the state, showcasing the reliability and efficiency of Nuvve's technology and the best-in-class features of our Thomas Jouley school bus."
Ignacio Ruiz, superintendent of Las Cruces Public Schools adds, "Our partnership with Nuvve reflects our shared commitment to sustainability and innovation. By transitioning to electric vehicles and leveraging Nuvve's advanced energy management solutions, we are taking important steps towards reducing environmental impacts. This collaboration aims to not only address climate change but also to create a healthier environment for our students."

NVVE

Nuvve and Las Cruces Schools Launch First Electric Bus Charging Project in New Mexico

HSBC analyst Charlene Liu downgrades Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) from Buy to Hold and announces $100 price target.

BIDU

HSBC Downgrades Baidu to Hold, Announces $100 Price Target

SCKT

Socket Mobile Says CaptureSDK And Its Entire Line Of Barcode Scanners And NFC Reader/Writers Have Been Thoroughly Tested And Have Achieved Full Compatibility With iOS 18

In Georgia, the company is collaborating with Kelly Family Distributor, the premier distributor for Black-owned wine and spirits brands, ensuring a robust foothold in the local market.

LiveOne Partners With SOKO, California's First Black-owned And Woman-owned Distributor, To Enhance Its Presence In California

TD Cowen analyst Tara Bancroft initiates coverage on Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Buy rating and announces Price Target of $65.

PTGX

TD Cowen Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $65

Needham analyst Scott Berg reiterates Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Buy and maintains $70 price target.

Reiteration

BRZE

Needham Reiterates Buy on Braze, Maintains $70 Price Target

Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a &#8220;miracle&#8221; weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year.
What Happened: Jorgensen is scheduled to testify before a <a href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on">Senate committee on Tuesday</a> to discuss U.S. pricing for Ozempic and the weight loss drug Wegovy. The comments align with Wall Street analysts&#8217; expectations that Ozempic will be on the 2027 price negotiation list, which will be announced in February 2025, Reuters reported.
Last week, another Novo executive indicated that Ozempic would &#8220;very likely&#8221; be included in the 2027 list. A month&#8217;s supply of Ozempic currently lists at $935.77 in the U.S., while Wegovy lists for $1,349.02 per month, although insurance often reduces these costs.
The Inflation Reduction Act of 2022 permits Medicare to negotiate prices for costly prescription drugs, impacting millions of Americans. Both Ozempic and Wegovy have faced scrutiny from lawmakers over their high prices in the U.S.
Jorgensen noted that the net price of Ozempic has decreased by about 40% since its U.S. introduction, and Wegovy&#8217;s net price has similarly declined since its launch. He expects net prices for both drugs to continue to fall under current market conditions.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40989263/long-term-medical-cannabis-use-has-no-significant-harmful-effects-on-memory-or-impulse-control-n?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Long-Term Medical Cannabis Use Has No Significant Harmful Effects On Memory Or Impulse Control, New Study</a>
Why It Matters: The upcoming Senate hearing, scheduled for Tuesday, will see Lars Fruergaard Jorgensen face rigorous questioning from U.S. lawmakers regarding the high prices of Ozempic and Wegovy. Senator Bernie Sanders, chair of the Senate Committee on Health, Education, Labor, and Pensions, has been vocal about the exorbitant costs of these medications.
In a previous interview, Jorgensen <a href="https://www.benzinga.com/general/biotech/24/08/40550961/novo-nordisk-does-not-operate-as-drug-cartel-ceo-defends-us-pricing-of-ozempic-against-criticism-">defended the high U.S. prices</a>, arguing that these drugs help reduce the economic burden of obesity-related health issues, which costs the U.S. over $400 billion annually. He dismissed accusations that Novo Nordisk operates as a drug cartel as &#8220;unfounded.&#8221; 
Additionally, the issue of counterfeit Ozempic has emerged as a significant concern. Criminals have been <a href="https://www.benzinga.com/general/biotech/24/09/40737027/fake-ozempic-targets-weight-loss-market-forged-batches-an-international-concern">distributing fake versions</a> of the drug by forging batch numbers, which has become an international issue. The World Health Organization and Interpol have both issued warnings about these counterfeit products. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Novo Nordisk And Corbus Pharmaceutical Stocks Plummet</a></li>
</ul>
Photo via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Inozyme Pharma GAAP EPS of -$0.44

Needham analyst Joseph Stringer reiterated a Buy rating on Inozyme Pharma (INZY – Research Report) today and set a price target of $23.00. Joseph S...

Inozyme Pharma: A Buy Rating Backed by Clinical Trials and Market Potential

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Inozyme Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/inzy-stock-quote/">INZY</a>) just reported results for the second quarter of 2024.<ul><li>Inozyme Pharma reported earnings per share of -44 cents. This was below the analyst estimate for EPS of -39 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/inzy-stock-earnings-inozyme-pharma-for-q2-of-2024/">INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024

TD Cowen analyst Marc Frahm has maintained their bullish stance on INZY stock, giving a Buy rating today. Marc Frahm has given his Buy rating due t...

Inozyme Pharma: A Buy Rating on the Horizon of Clinical Advancements and Financial Stability

H.C. Wainwright analyst Edward White reiterated a Buy rating on Inozyme Pharma (INZY – Research Report) today and set a price target of $14.00. Edw...

Inozyme Pharma: A Strong Buy on Promising Treatments for Rare Disorders

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tango Therapeutics (TNGX – Research Report), Inozyme...

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)

Inozyme draws Buy at Jefferies on rare disease opportunity

While inflation has eased to 2.9% in July, interest rates remain elevated, with the Federal Reserve's key rate currently at 5.25% to 5.50%. However...

Jefferies Predicts up to 270% Rally for These 2 'Strong Buy' Stocks

Inozyme draws buy at Stifel on lead asset

TNGX

Press Releases

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

Inozyme Pharma to Present at the Jefferies Global Healthcare Conference

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Inozyme Pharma

Inozyme Pharma (INZY) Forecast

Inozyme Pharma (NASDAQ:INZY) Stock, Quote.Headers.trade-ideas